Profile

Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class accurate editing efficiency, undetectable off-target effects, and true plug-and-play programmability with broad therapeutic potential as in vivo medicines with proof-of-concept in preclinical animal models. Dualase®’s two-site mechanism enables seamless removal, repair and insertion of small or large sequences. Their differentiated pipeline of developments candidates addresses mutations that other genome editors cannot, with an initial focus on repeat expansion disorders in neurodegenerative disease.

Specific Biologics Inc. logo
specificbiologics.com

Contact

Event details

Date: June 16 - 19, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

23 in total
  • 20/20 OptimEyes Technologies Inc.
    20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
  • BIOScript/ACCELERA
    Since 2001, BioScript Solutions has supported patients with chronic illnesses and rare diseases by providing…
  • Custom Biologics
    Custom Biologics provides regulatory compliant potency testing and assay services for all phases of…
  • Dalriada Drug Discovery
    Dalriada is a leading North American discovery company pioneering its novel Turn-Key™ model in small molecule…
  • HDAX Therapeutics
    HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address…
  • ImmunoBiochem Corporation
    ImmunoBiochem is an innovative biopharmaceutical company developing novel bioconjugate therapeutics, such …
  • Invest Ontario
    Invest Ontario is a provincial agency dedicated to securing private sector strategic business and capital…
  • Lumerate
    Raising capital is a key challenge for executives at early-stage therapeutics companies. Lumerate is launching…
  • mDETECT
    mDETECT offers highly sensitive and cost-effective blood tests that can measure tumour behaviour irrespective of…
  • Noa Therapeutics
    Noa Therapeutics is a preclinical biotech company pioneering the development of homeostatic modulating small…
  • Nucro-Technics
    Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP…
  • Paradox Immunotherapeutics
    Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead…
  • QReserve
    QReserve provides powerful enterprise-grade scheduling and resource management software to world-class…
  • Specific Biologics Inc.
    Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class…
  • Spiderwort Biotechnologies
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • Stiris Research Inc.
    Stiris is a clinical trial management company conducting Phase I-IIIB trials for biotech and…
  • Sussex Research Laboratories Inc.
    Sussex Research Laboratories Inc. (Ottawa, Canada) is recognized as a leader in the design and synthesis of…
  • SYNG Pharma
    SYNG Pharma is developing a new first-in-class diagnostic test and non-hormonal therapy for endometriosis. The…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…
  • VeriLuce Therapeutics Inc.
    VeriLuce Therapeutics is an early-stage drug company developing novel small molecules targeting in dual…
  • Virano Therapeutics
    Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the…
  • YYZ Pharmatech Inc.
    YYZ Pharmatech Inc. (“YYZ”) is a deep tech company endeavoring to profoundly progress…